---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Taxane and platinum chemotherapy"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Taxane and platinum chemotherapy. Topics: Docetaxel: FDA-approved indication and TAX327 overall survival, Docetaxel: TAX327 publication, Cabazitaxel: FDA-approved indication and TROPIC overall survival, Cabazitaxel: TROPIC publication, and 5 further topics. 9 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/taxane-and-platinum-chemotherapy"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Taxane and platinum chemotherapy

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 Taxane and Platinum Chemotherapy

<a id="topic-2.2.2.1.3-1"></a>

### Docetaxel: FDA-approved indication and TAX327 overall survival

> “TAXOTERE in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.”
> “For metastatic castration-resistant prostate cancer, the recommended dose of TAXOTERE is 75 mg/m2 every 3 weeks as a 1 hour intravenous infusion.”

Source: [Taxotere prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020449s086lbl.pdf)

| Outcome | Docetaxel plus prednisone every 3 weeks | Mitoxantrone plus prednisone every 3 weeks |
| --- | --- | --- |
| Median survival, months (95% CI) | “18.9 (17.0-21.2)” | “16.5 (14.4-18.6)” |
| Hazard ratio (95% CI) | “0.761 (0.619-0.936)” | Not applicable |

Source: [Taxotere prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020449s086lbl.pdf)

<a id="topic-2.2.2.1.3-2"></a>

### Docetaxel: TAX327 publication

> “As compared with the men in the mitoxantrone group, men in the group given docetaxel every three weeks had a hazard ratio for death of 0.76 (95 percent confidence interval, 0.62 to 0.94; P=0.009 by the stratified log-rank test)”
> “Among these three groups, 32 percent, 45 percent, and 48 percent of men, respectively, had at least a 50 percent decrease in the serum PSA level (P<0.001 for both comparisons with mitoxantrone)”

Source: [Tannock et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15470213/)

<a id="topic-2.2.2.1.3-3"></a>

### Cabazitaxel: FDA-approved indication and TROPIC overall survival

> “JEVTANA® is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.”

Source: [Jevtana prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201023s026lbl.pdf)

| Outcome | Cabazitaxel plus prednisone | Mitoxantrone plus prednisone |
| --- | --- | --- |
| Median survival, months (95% CI) | “15.1 (14.1-16.3)” | “12.7 (11.6-13.7)” |
| Hazard ratio (95% CI) | “0.70 (0.59-0.83)” | Not applicable |

Source: [Jevtana prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201023s026lbl.pdf)

<a id="topic-2.2.2.1.3-4"></a>

### Cabazitaxel: TROPIC publication

> “At the cutoff for the final analysis (Sept 25, 2009), median survival was 15·1 months (95% CI 14·1-16·3) in the cabazitaxel group and 12·7 months (11·6-13·7) in the mitoxantrone group.”
> “The most common clinically significant grade 3 or higher adverse events were neutropenia (cabazitaxel, 303 [82%] patients vs mitoxantrone, 215 [58%]) and diarrhoea (23 [6%] vs one [<1%]).”

Source: [de Bono et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20888992/)

<a id="topic-2.2.2.1.3-5"></a>

### Cabazitaxel versus a second androgen receptor pathway inhibitor after docetaxel: CARD

> “in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen and had progressed within 12 months of initiating either abiraterone or enzalutamide.”

Source: [Jevtana prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201023s026lbl.pdf)

| Outcome | Cabazitaxel plus prednisone or prednisolone plus G-CSF | Abiraterone plus prednisone or prednisolone, or enzalutamide |
| --- | --- | --- |
| Median rPFS, months (95% CI) | “8.0 (5.7 to 9.2)” | “3.7 (2.8 to 5.1)” |
| rPFS hazard ratio (95% CI) | “0.54 (0.40 to 0.73)” | Not applicable |
| Median OS, months (95% CI) | “13.6 [11.5; 17.5]” | “11.0 [9.2; 12.9]” |
| OS hazard ratio (95% CI) | “0.64 [0.46; 0.89]” | Not applicable |

Source: [Jevtana prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201023s026lbl.pdf)

<a id="topic-2.2.2.1.3-6"></a>

### Cabazitaxel versus a second androgen receptor pathway inhibitor: CARD publication

> “Adverse events of grade 3 or higher occurred in 56.3% of patients receiving cabazitaxel and in 52.4% of those receiving an androgen-signaling-targeted inhibitor.”
> “tumor response was noted in 36.5% and 11.5% (P = 0.004)”

Source: [de Wit et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31566937/)

<a id="topic-2.2.2.1.3-7"></a>

### Guideline statements on chemotherapy after androgen receptor pathway inhibitors

> “Offer chemotherapy to patients previously treated with an androgen receptor pathway inhibitor (ARPI).”
> “Offer patients with metastatic castrate-resistant PCa (mCRPC) who are candidates for cytotoxic therapy and are chemotherapy naïve docetaxel with 75 mg/m 2 every three weeks.”
> “Offer cabazitaxel to patients previously treated with docetaxel who have progressed within 12 months of treatment with abiraterone or enzalutamide for mCRPC.”
> “The use of chemotherapy with docetaxel and subsequent cabazitaxel in the treatment sequence is recommended and should be applied early enough when the patient is still fit for chemotherapy.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.3-8"></a>

### Platinum chemotherapy: guideline treatment-selection factors

> “known histological variants and DNA repair deficiency (to consider platinum or targeted therapy like PARPi);”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.3-9"></a>

### Carboplatin added to cabazitaxel: randomized phase 2 trial

> “At a median follow-up of 31·0 months (IQR 20·5–37·1), the combination improved the median progression-free survival from 4·5 months (95% CI 3·5–5·7) to 7·3 months (95% CI 5·5–8·2; hazard ratio 0·69, 95% CI 0·50–0·95, p=0·018).”
> “In the phase 2 study, the most common grade 3–5 adverse events were fatigue (7 [9%] of 79 in the cabazitaxel group vs 16 [20%] of 81 in the combination group), anaemia (3 [4%] vs 19 [23%]), neutropenia (3 [4%] vs 13 [16%]), and thrombocytopenia (1 [1%] vs 11 [14%]).”

Source: [Corn et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6858999/)

Additional sources: [AUA (2026)](https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer); [Fizazi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41679466/); [NCCN (2026)](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf); [Annala et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33836265/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
